United Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Raised by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board raised its stake in United Therapeutics Co. (NASDAQ:UTHR) by 567.2% in the 1st quarter, Holdings Channel.com reports. The firm owned 180,800 shares of the biotechnology company’s stock after acquiring an additional 153,700 shares during the period. Canada Pension Plan Investment Board’s holdings in United Therapeutics were worth $41,533,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rise Advisors LLC bought a new stake in shares of United Therapeutics in the 1st quarter worth about $32,000. GAMMA Investing LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $43,000. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares during the period. Janiczek Wealth Management LLC boosted its holdings in shares of United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 84 shares during the period. Finally, Blue Trust Inc. boosted its holdings in shares of United Therapeutics by 10.0% in the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the sale, the director now directly owns 4,185 shares in the company, valued at approximately $1,087,723.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total value of $929,124.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $33,551.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the sale, the director now owns 4,185 shares in the company, valued at $1,087,723.35. The disclosure for this sale can be found here. In the last three months, insiders sold 100,884 shares of company stock valued at $29,622,803. Company insiders own 12.50% of the company’s stock.

United Therapeutics Trading Up 0.5 %

Shares of NASDAQ:UTHR opened at $338.22 on Friday. The company has a 50 day moving average of $303.01 and a 200-day moving average of $257.47. The firm has a market cap of $15.00 billion, a P/E ratio of 15.99, a P/E/G ratio of 1.48 and a beta of 0.55. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $343.98. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period in the prior year, the business posted $4.86 EPS. As a group, analysts anticipate that United Therapeutics Co. will post 24.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. UBS Group lifted their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. HC Wainwright boosted their target price on shares of United Therapeutics from $300.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday. Oppenheimer boosted their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, May 21st. Finally, Wells Fargo & Company boosted their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, June 12th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $330.64.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.